Sequence dependence of cell growth inhibition by EGFR–tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer

C. Klass,Mison Choe,S. Hurwitz,M. Tighiouart,Xin Zhang,Z. Chen,D. Shin

DOI: https://doi.org/10.1002/hed.21103

2009-10-01

Head and Neck

Abstract:This study was to explore whether the efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination.

Medicine